Bassem I Razzouk
Overview
Explore the profile of Bassem I Razzouk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
1750
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leger K, Absalon M, Demissei B, Smith A, Gerbing R, Alonzo T, et al.
Front Cardiovasc Med
. 2024 Jul;
11:1347547.
PMID: 38947228
Introduction: Anthracyclines are effective in treating acute myeloid leukemia (AML) but limited by cardiotoxicity. CPX-351, a liposomal daunorubicin and cytarabine, may provide therapeutic benefit with less cardiotoxicity. Acute changes in...
2.
Kokoska R, Beltz E, Smith J, Razzouk B
Pediatr Hematol Oncol
. 2021 May;
39(1):62-67.
PMID: 33988076
This case report presents the first reported pediatric case of primary classical nodular sclerosing Hodgkin Lymphoma (HL) with pineal gland involvement, presenting without CNS symptoms, which completely resolved after 2...
3.
Cooper T, Absalon M, Alonzo T, Gerbing R, Leger K, Hirsch B, et al.
J Clin Oncol
. 2020 May;
38(19):2170-2177.
PMID: 32401633
Purpose: Effective regimens are needed for children with relapsed acute myeloid leukemia (AML). AAML1421 is a phase I/II study of CPX-351, a liposomal preparation of daunorubicin and cytarabine. AAML1421 sought...
4.
Cooper T, Alonzo T, Gerbing R, Perentesis J, Whitlock J, Taub J, et al.
Cancer
. 2014 Apr;
120(16):2482-9.
PMID: 24771494
Background: The discovery of new, effective non-anthracycline-based reinduction regimens for children with recurrent acute myeloid leukemia (AML) is critical. In this phase 1/2 study, the tolerability and overall response rate...
5.
Cooper T, Razzouk B, Gerbing R, Alonzo T, Adlard K, Raetz E, et al.
Pediatr Blood Cancer
. 2013 Jan;
60(7):1141-7.
PMID: 23335239
Background: The discovery of effective re-induction regimens for children with more than one relapse of acute lymphoblastic leukemia (ALL) remains elusive. The novel nucleoside analog clofarabine exhibits modest single agent...
6.
Kaspers G, Zimmermann M, Reinhardt D, Gibson B, Tamminga R, Aleinikova O, et al.
J Clin Oncol
. 2013 Jan;
31(5):599-607.
PMID: 23319696
Purpose: In pediatric relapsed acute myeloid leukemia (AML), optimal reinduction therapy is unknown. Studies suggest that liposomal daunorubicin (DNX; DaunoXome; Galen, Craigavon, United Kingdom) is effective and less cardiotoxic, which...
7.
Lamba J, Crews K, Pounds S, Cao X, Gandhi V, Plunkett W, et al.
Pharmacogenomics
. 2011 Apr;
12(3):327-39.
PMID: 21449673
Aim: To identify gene-expression signatures predicting cytarabine response by an integrative analysis of multiple clinical and pharmacological end points in acute myeloid leukemia (AML) patients. Materials & Methods: We performed...
8.
Inaba H, Cao X, Pounds S, Pui C, Rubnitz J, Ribeiro R, et al.
Cancer
. 2011 Mar;
117(6):1313-20.
PMID: 21381017
Background: Granulocyte-colony-stimulating factor (G-CSF) is effective in accelerating neutrophil recovery after intensive chemotherapy for acute myeloid leukemia (AML). However, the optimal G-CSF dosage for patients with AML has not been...
9.
Rubnitz J, Inaba H, Dahl G, Ribeiro R, Bowman W, Taub J, et al.
Lancet Oncol
. 2010 May;
11(6):543-52.
PMID: 20451454
Background: We sought to improve outcome in patients with childhood acute myeloid leukaemia (AML) by applying risk-directed therapy that was based on genetic abnormalities of the leukaemic cells and measurements...
10.
Inaba H, Stewart C, Crews K, Yang S, Pounds S, Pui C, et al.
Cancer
. 2009 Nov;
116(1):98-105.
PMID: 19885837
Background: The prognosis after recurrence of pediatric acute myeloid leukemia (AML) is poor, and effective salvage regimens are urgently needed. Methods: In phase 1 and pilot studies, the authors evaluated...